Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection

Int J Gynaecol Obstet. 1994 Jun;45(3):235-9. doi: 10.1016/0020-7292(94)90248-8.

Abstract

Objectives: To evaluate the effects of treatment with the gonadotropin releasing hormone (GnRH) agonist goserelin before endometrial resection on absorption of distension medium fluid and technical feasibility of the surgical procedure.

Methods: Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls).

Results: In the cases, the mean distension medium deficit +/- S.D. was 511 +/- 196 ml versus 647 +/- 245 ml in controls (P = 0.03), and the operating times were, respectively, 14 +/- 4 versus 18 +/- 5 min (P = 0.002). The intrauterine operating conditions were considered excellent or good in 64% of the cases versus 27% of the controls (chi 2 = 5.60, P = 0.02).

Conclusions: GnRH agonists induce endometrial thinning, so that when administered before intrauterine interventions, mucus cellular debris and bleeding should be reduced during surgery and hysteroscopic visibility increased; the operating time may thus be shorter and fluid absorption decreased. However, more data are needed before considering GnRH agonists a proven effective means of facilitating endometrial resection.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Endometrium / surgery*
  • Female
  • Goserelin / therapeutic use*
  • Humans
  • Hysteroscopy*
  • Menorrhagia / surgery*
  • Middle Aged
  • Preoperative Care*

Substances

  • Goserelin